Comparative Study of Rinsulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method

A Double-blinded, Randomized, Comparative, Crossover Pharmacokinetics Study of Rinsulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (Lilly France, France) Using Method of Euglycemic Hyperinsulinemic Clamp on Healthy Volunteers

Сomparative pharmacokinetic study of Rinsulin® NPH, suspension for subcutaneous administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, suspension for subcutaneous administration, 100 IU/ml (Lilly France, France) using the euglycemic hyperinsulinemic clamp.

Study Overview

• Status: Completed
• Conditions: Pharmacokinetics; Bioequivalence
• Intervention / Treatment: Drug: Rinsulin NPH; Drug: Humulin NPH

Detailed Description

A double-blinded, randomized, comparative, crossover pharmacokinetics study of Rinsulin® NPH, suspension for subcutaneous administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, suspension for subcutaneous administration, 100 IU/ml (Lilly France, France) using method of euglycemic hyperinsulinemic clamp on healthy volunteers

• Study Type: Interventional
• Enrollment (Actual): 52
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Russian Federation
  • Yaroslavl, Russian Federation
    • Yarosslavl Clinical Hospital #3

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Signed informed consent to participate in the study.
• Men of the Caucasian race with a verified diagnosis "healthy" according to the data of standard clinical, laboratory and instrumental examination methods.
• Age 18-50, inclusive.
• Body mass index 18.5 - 27 kg / m2.
• Volunteers who have sexual contact with fertile women should agree to use barrier methods of contraception while participating in the study (unless they have undergone surgical sterilization). Study Participants must also not become a sperm donor within the specified period.
• Consent to all restrictions imposed during the study.

Exclusion Criteria:

• Acute inflammatory diseases within 3 weeks from the moment of complete recovery to the stage of screening.
• Presence of episodes of hypoglycemia in the history of the volunteer
• Presence in the family history of the closest relatives cases of verified diagnosis of diabetes mellitus of any type.
• Deviations from the norm of basic vital indicators (heart rate, blood pressure, respiratory rate, body temperature) and ECG from normal values and laboratory values from reference values during screening.
• Fasting plasma glucose> 6.1 mmol / L at screening.
• HbA1C> 6% at the time of screening.
• Oral glucose tolerance test - blood glucose level ≥7.8 mmol / L (2 hours after glucose loading) during screening.
• Hard-to-reach veins of the upper extremities, vein thrombosis, history of thrombophlebitis or family history of close relatives, "compromised" veins due to frequent preceding venipuncture.
• Taking medications, phytopreparations, biologically active additives within 14 days before screening.
• Significant blood loss 3 months before screening due to, for example, but not limited to the following points: a. donor blood donation; b. extended surgery or trauma leading to significant blood loss.
• Incomplete recovery from surgery or surgery scheduled while the volunteer is participating in the study.
• Mental, physical and other reasons interferes with adequately assessing behavior and correctly fulfill the conditions of the research protocol (incl. a history of mental illness).
• Presence or history (three years before the the study drug) of narcotic, drug and / or substance abuse.
• Positive test for the content of narcotic drugs in urine during the screening period.
• Anamnestic information about alcoholism or taking more than 10 units. alcohol per week (1 unit of alcohol is equivalent to 0.5 liters of beer, 200 ml of dry wine or 50 ml of spirits).
• Positive test for alcohol in breath during screening.
• Nicotine addiction (regular use of tobacco less than 6 months before screening).
• Any chronic diseases, incl. but not limited to positive test results for hepatitis C or hepatitis B, HIV, syphilis at the time of screening.
• Burdened allergological history.
• presence of suspicion of an inflammatory disease of the urinary system based on the results of urinalysis during screening.
• Presence of oncological diseases within 5 years before the screening.
• History of organ transplantation (except of corneal transplant performed more than 3 months before the first injection of the study drug).
• Participation in a clinical trial of any drug or experimental medical device within 3 months prior to the first administration of the study drug.
• Any other condition that, in the reasonable opinion of the research physician, makes it difficult for the volunteer to participate in the study.
• History of hypersensitivity to heparin, insulin or any of the excipients of the investigational drugs.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: BASIC_SCIENCE
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: DOUBLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Rinsulin® NPH; Single subcutaneous administration of Insulin at a dose 0.4 IU / kg	Drug: Rinsulin NPH; subcutaneous injection at a dose of 0.4 IU/kg; Drug: Humulin NPH; subcutaneous injection at a dose of 0.4 IU/kg
ACTIVE_COMPARATOR: Humulin® NPH; Single subcutaneous administration of Insulin at a dose 0.4 IU / kg	Drug: Rinsulin NPH; subcutaneous injection at a dose of 0.4 IU/kg; Drug: Humulin NPH; subcutaneous injection at a dose of 0.4 IU/kg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Смах	Test Drug Observed Maximum Plasma Concentration (Cmax)	- 1 , -0.5 , 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24 hours
AUC 0-12	Total area under the curve "drug concentration - time" in the time interval from 0 to 12 h	- 1 , -0.5 , 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24 hours
AUC GIR 0-12	Total area under the curve "glucose infusion rate - time" in the time interval from 0 to 12 h	-2, -1.5, 1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour
AUC GIR 0-24	Total area under the curve "glucose infusion rate - time" in the time interval from 0 to 24 h	-2, -1.5, 1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour
GIRmax	Maximum glucose infusion rate over the study period	-2, -1.5, 1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour
tGIRmax	Time to reach maximum glucose infusion rate	-2, -1.5, 1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour
tGIRlag	Time between the drug administration and the onset of action	-2, -1.5, 1, -0.5, then every 5 min till 10 hour, every 10 min till 12 hour, every 15 min till 24 hour

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUC 0-2	Total area under the curve "drug concentration - time" in the time interval from 0 to 2 h	- 1 , -0.5 , 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24 hours
AUC 0-6	Total area under the curve "drug concentration - time" in the time interval from 0 to 6 h	- 1 , -0.5 , 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24 hours
AUC 0-24	Total area under the curve "drug concentration - time" in the time interval from 0 to 24 h	- 1 , -0.5 , 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24 hours
AUC 0-∞	Total area under the curve "drug concentration - time" in the time interval from 0 to ∞	- 1 , -0.5 , 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24 hours
Tmax	Time to reach test drug Maximum Plasma Concentration	- 1 , -0.5 , 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24 hours
T1/2	Half-life of a drug tested	- 1 , -0.5 , 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, 24 hours

Collaborators and Investigators

• Sponsor: Geropharm
• Investigators: Principal Investigator: Sergei Mr Noskov, AP of medicine, Yaroslavl City Clinical Hospital No. 3

Study record dates

Study Major Dates

• Study Start (ACTUAL): October 23, 2017
• Primary Completion (ACTUAL): January 1, 2018
• Study Completion (ACTUAL): May 21, 2018

Study Registration Dates

• First Submitted: August 3, 2020
• First Submitted That Met QC Criteria: August 3, 2020
• First Posted (ACTUAL): August 6, 2020

Study Record Updates

• Last Update Posted (ACTUAL): August 6, 2020
• Last Update Submitted That Met QC Criteria: August 3, 2020
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Keywords: euglycemic hyperinsulinemic clamp; human recombinant insulin
• Additional Relevant MeSH Terms: Hypoglycemic Agents; Physiological Effects of Drugs; Insulin; Insulin, Globin Zinc
• Other Study ID Numbers: RINCL-NPH

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No